- Home
- PLRX vs STRO Comparison
PLRX vs STRO Comparison
Compare PLRX & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | STRO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 85.0M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLRX | STRO |
|---|---|---|
| Price | $1.27 | $16.11 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 11 | 8 |
| Target Price | $3.79 | ★ $18.88 |
| AVG Volume (30 Days) | ★ 1.0M | 130.0K |
| Earning Date | 03-02-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $105,646,000.00 |
| Revenue This Year | N/A | $63.08 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $5.23 |
| 52 Week High | $12.88 | $21.25 |
Technical Indicators
Market Signals| Indicator | PLRX | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 44.77 | 68.77 |
| Support Level | $1.26 | $14.08 |
| Resistance Level | $1.36 | $17.33 |
| Average True Range (ATR) | 0.06 | 1.47 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 17.86 | 78.71 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.